Lamivudine/tenofovir disoproxil fumarate

Drug Profile

Lamivudine/tenofovir disoproxil fumarate

Latest Information Update: 12 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer INSERM; Merck Sharp & Dohme; UNITAID
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 12 Dec 2016 Chemical structure information added
  • 28 Nov 2016 Merck Sharp & Dohme plans a phase I trial for HIV-1 infections (In volunteers) in Canada (PO) (EudraCT2016-004392-41)
  • 01 Jul 2016 Phase-III clinical trials in HIV-1 infections in Cameroon (PO) (NCT02777229)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top